PTGX — Protagonist Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $3.29bn
- $2.71bn
- $434.43m
- 73
- 33
- 83
- 68
Annual income statement for Protagonist Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 28.6 | 27.4 | 26.6 | 60 | 434 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 93.7 | 153 | 158 | 154 | 182 |
| Operating Profit | -65.1 | -126 | -131 | -93.7 | 253 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -64.8 | -126 | -127 | -79 | 279 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -66.2 | -126 | -127 | -79 | 275 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -66.2 | -126 | -127 | -79 | 275 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -66.2 | -126 | -127 | -79 | 275 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.91 | -2.71 | -2.6 | -1.39 | 4.23 |